Mechanistic Commercial Validation of Kiwifruit-Derived Digestive Health Supplements Through CytoSolve® Systems Biology for Anagenix Group Enabling Evidence-Based Gut Motility Insights

Anagenix Group is a nutrition-focused company developing wholefood-based dietary supplements backed by clinical and experimental science. Its flagship products, Actazin™ and Livaux™, are derived from green and gold kiwifruit and are clinically shown to support digestive health.

Challenge

Although clinical and experimental studies demonstrated positive digestive health effects of Actazin™ and Livaux™, the molecular mechanisms underlying these benefits—both individually and in combination—were not fully understood. The absence of a mechanistic, systems-level explanation limited the ability to substantiate synergistic claims, optimize formulation strategies, and support robust, science-driven commercialization of multi-ingredient nutritional supplements

How CytoSolve Helped

CytoSolve collaborated with Anagenix Group to establish a mechanistic foundation for gut motility enhancement using its computational systems biology platform. CytoSolve:

  • Conducted a systematic literature review to identify molecular pathways governing gut motility.
  • Translated key pathways into individual mathematical models representing biological subsystems.
  • Independently validated each pathway model using published experimental data.
  • Dynamically integrated the validated models within the CytoSolve® platform to create an integrative, systems-level gut motility model.
  • Simulated the combined effects of all identified bioactive molecules in Actazin™ and Livaux™ at recommended dose levels to assess synergistic interactions in silico.

Key Benefits Realized

  • Systems-Level Understanding of Gut Motility
    Identified three primary biological systems regulating gut motility: inflammation, mucus production, and fecal bulking.
  • Mechanistic Validation of Synergy
    Demonstrated that Actazin™ bioactive compounds synergistically enhance gut motility rather than acting through isolated mechanisms.
  • Molecular Substantiation of Health Benefits
    Showed reduced inflammation, increased mucus production, and elevated expression of PYY and GLP-1—key regulators of gut transit time and fecal bulking.
  • Commercial Claim Support
    Provided a rigorous, mechanistic framework to support science-backed digestive health positioning.
  • Reduced Development Risk
    Enabled in silico testing of multi-ingredient combinations prior to costly experimental studies.

Outcome

Through its collaboration with CytoSolve®, Anagenix Group achieved a validated, integrative systems biology model explaining how Actazin™ and Livaux™ improve gut motility at the molecular level. This work translated clinical observations into mechanistic insight, demonstrating synergistic effects across inflammation control, mucus production, and fecal bulking pathways. The resulting computational evidence base strengthened commercialization strategy, reinforced scientific credibility, and exemplified how CytoSolve® transforms complex nutritional biology into actionable, market-ready validation for functional food and supplement innovators.